Molecular and biologic biomarkers of Ewing sarcoma: A systematic review

Mohammad Daher; Ziad Zalaquett; Ralph Chalhoub; Sami Abi Farraj; Majd Abdo; Amer Sebaaly; Hampig-Raphaël Kourie; Ismat Ghanem

doi:10.1016/j.jbo.2023.100482

Molecular and biologic biomarkers of Ewing sarcoma: A systematic review

J Bone Oncol. 2023 Apr 26:40:100482. doi: 10.1016/j.jbo.2023.100482. eCollection 2023 Jun.

Authors

Mohammad Daher¹, Ziad Zalaquett², Ralph Chalhoub², Sami Abi Farraj¹, Majd Abdo², Amer Sebaaly¹, Hampig-Raphaël Kourie², Ismat Ghanem¹

Affiliations

¹ Orthopedic Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
² Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.

Abstract

With an annual incidence of less than 1%, Ewing sarcoma mainly occurs in children and young adults. It is not a frequent tumor but is the second most common bone malignancy in children. It has a 5-year survival rate of 65-75%; however, it has a poor prognosis when it relapses in patients. A genomic profile of this tumor can potentially help identify poor prognosis patients earlier and guide their treatment. A systematic review of the articles concerning genetic biomarkers in Ewing sarcoma was conducted using the Google Scholar, Cochrane, and PubMed database. There were 71 articles discovered. Numerous diagnostic, prognostic, and predictive biomarkers were found. However, more research is necessary to confirm the role of some of the mentioned biomarkers. .

Keywords: Biologic; Biomarkers; Bone tumors; Ewing sarcoma; Genes; Molecular.

Publication types

Review